Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.
Amylyx Pharmaceuticals, Inc. (AMLX) Cost of Goods Sold data is not available for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-144.74M |
|
|
Cost of Goods Sold |
-- |
-- |
|
$153.29M |
|
$-153.29M |
|
$8.60M |
|
$-144.69M |
|
$-144.69M |
|
$-144.74M |
|
$-144.74M |
|
$-144.74M |
|
$-144.74M |
|
$-153.29M |
|
$-158.29M |
|
94.57M |
|
94.57M |
|
$-1.53 |
|
$-1.53 |
|
| Balance Sheet Financials | |
$323.67M |
|
$0.31M |
|
$8.97M |
|
$332.64M |
|
$22.69M |
|
-- |
|
$4.70M |
|
$27.39M |
|
$305.26M |
|
$305.26M |
|
$305.26M |
|
109.89M |
|
| Cash Flow Statement Financials | |
$-123.34M |
|
$14.04M |
|
$257.03M |
|
$78.84M |
|
$227.64M |
|
$148.80M |
|
$27.64M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.27 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-123.48M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-47.41% |
|
-47.41% |
|
-43.51% |
|
-47.41% |
|
$2.78 |
|
$-1.31 |
|
$-1.30 |
|